Ranbaxy announces marketing of Evista

Ranbaxy and Daiichi Sankyo have jointly announced that the marketing of Evista will be handled by the Ranbaxy subsidiary Terapia.

This move relating to the drug, which is used for the treatment of osteoporosis, marks the first time that Daiichi Sankyo and Ranbaxy have leveraged synergies generated through the hybrid business model in Europe.

President and chief executive of Daiichi Sankyo Takashi Shoda said that the firm is hoping to explore further opportunities with Ranbaxy in the future.

Similarly, Atul Sobti, chief executive and managing director of Ranbaxy, stated: “Terapia Ranbaxy is a strong player in Europe and we will provide a unique platform to Daiichi Sankyo for the launch of Evista and many more new products in the future.”

Last month, Ranbaxy announced that it had received approval from the Food and Drug Administration to manufacture Sumatriptan Succinate tablets in doses of 25 mg and 50 mg. The drug is a treatment for adult migraine attacks with or without aura.